Sugi Predict

Sugi Predict / Compounds / SCHEMBL930442

SCHEMBL930442

SCHEMBL930442

c1ccc2c(c1)CCN2c1cc2ccccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ BRCA1 P38398 1/20 0.55
▸ ALDH1A1 P00352 5/20 0.52
▸ HPGD P15428 4/20 0.52
▸ KDM4C Q9H3R0 2/20 0.52
▸ MEN1 O00255 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ KDM4A O75164 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ AOC3 Q16853 2/20 0.44
▸ ROCK1 Q13464 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ RAB9A P51151 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29713612 1.00 TSHR (0.55) TSHRALOX15BRCA1ALDH1A1HPGD
SCHEMBL7715904 0.91 TSHR (0.46) TSHRALOX15BRCA1ALDH1A1HPGD
Trifluoromethanesulfonic Acid SCHEMBL21408184 0.86 TSHR (0.46) TSHRALOX15BRCA1ALDH1A1HPGD
Trifluoromethanesulfonic Acid SCHEMBL30159123 0.86 TSHR (0.46) TSHRALOX15BRCA1ALDH1A1HPGD
SCHEMBL7384299 0.86 TSHR (0.43) TSHRALOX15BRCA1ALDH1A1HPGD
SCHEMBL5362411 0.80 TSHR (0.56) TSHRALOX15BRCA1ALDH1A1HPGD
SCHEMBL27889736 0.73 AOC3 (0.46) HPGDMAPTKDM4EHSD17B10AOC3
SCHEMBL27946461 0.73 ALDH1A1 (0.43) TSHRALOX15BRCA1ALDH1A1HPGD
SCHEMBL9462932 0.72 AOC3 (0.41) TSHRALDH1A1HPGDMAPTKDM4E
SCHEMBL6789042 0.71 AOC3 (0.40) ALDH1A1HPGDMAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11951147-B2 SMAC mimetic MEDIVIR AB (SE) 2024-04-09 — — US disclosed
US-20230149500-A1 SMAC MIMETIC MEDIVIR AB (SE) 2023-05-18 — — US disclosed
US-11351221-B2 SMAC mimetic MEDIVIR AB (SE) 2022-06-07 — — US disclosed
US-20200282002-A1 SMAC Mimetic MEDIVIR AB (SE) 2020-09-10 — — US disclosed
US-10596220-B2 SMAC mimetic MEDIVIR AB (SE) 2020-03-24 — — US disclosed
US-20190255139-A1 SMAC Mimetic MEDIVIR AB (SE) 2019-08-22 — — US disclosed
US-10314881-B2 SMAC mimetic MEDIVIR AB (SE) 2019-06-11 — — US disclosed
US-20180303897-A1 SMAC Mimetic MEDIVIR AB (SE) 2018-10-25 — — US disclosed
US-10034912-B2 SMAC Mimetic TetraLogic Birinapant UK Ltd. (GB) 2018-07-31 — — US disclosed
US-9920093-B2 Dimeric IAP inhibitors TetraLogic Birinapant UK Ltd. (GB) 2018-03-20 — — US disclosed
EP-2385038-A1 Dimeric IAP inhibitors Tetralogic Pharmaceuticals Corporation (US) 2011-11-09 — — EP disclosed
US-8022230-B2 Dimeric IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-09-20 — — US disclosed
US-20110003877-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-01-06 — — US disclosed
WO-2011002684-A1 SMAC MIMETIC TETRALOGIC PHARMACEUTICALS CORP. (US) 2011-01-06 — — WO disclosed
US-20100075911-A1 DIMERIC IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2010-03-25 — — US disclosed
US-7517906-B2 Dimeric IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2009-04-14 — — US disclosed
EP-1851200-A2 DIMERIC IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2007-11-07 — — EP disclosed
US-20060194741-A1 Dimeric IAP inhibitors MEDIVIR AB (SE) 2006-08-31 — — US disclosed
WO-2006091972-A2 DIMERIC IAP INHIBITORS TETRALOGIC PHARMACEUTICALS (US) 2006-08-31 — — WO disclosed
US-4000304-A Diuretic antiturombogenic and antiarrhythmic processes using N-substituted indole dimers and pyrrolobenzodia-zepine rearrangement products thereof MEAD JOHNSON & COMPANY (US) 1976-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10596220-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20110003877-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-10314881-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20100075911-A1 DIMERIC IAP INHIBITORS BIRC2, XIAP, BIRC5 TSHR 4112/4885ALOX15 4246/4885BRCA1 176/4885
US-11951147-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-10034912-B2 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20060194741-A1 Dimeric IAP inhibitors BIRC2, BIRC3, BIRC5 TSHR 4332/4885ALOX15 3510/4885BRCA1 257/4885
US-20230149500-A1 SMAC MIMETIC SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-11351221-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20200282002-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20190255139-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885
US-20180303897-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TSHR 3929/4885ALOX15 4629/4885BRCA1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.